Company

Livzon Pharma's LZSN2501 Wins NMPA Clinical Trial Approval for VTE Prevention After Knee Arthroplasty – Bi-Epitopic Bispecific Anti-FXI Antibody Targets Next-Generation Anticoagulation
Clinical trial approval / initiationLivzon Pharmaceutical

Livzon Pharma’s LZSN2501 Wins NMPA Clinical Trial Approval for VTE Prevention After Knee Arthroplasty – Bi-Epitopic Bispecific Anti-FXI Antibody Targets Next-Generation Anticoagulation

Livzon Pharmaceutical Group Inc. (SHE: 000513) announced that its recombinant humanized anti-coagulation factor XI (FXI) bispecific antibody, LZSN2501, has received clinical trial approval from China's National Medical Products Administration (NMPA)…

GeneScience's GenSci136 Wins NMPA Clinical Trial Approval for Sjögren's Syndrome – Proprietary Dual-Target BAFF/APRIL Antagonist Advances Changchun High-Tech's Autoimmune Pipeline

GeneScience’s GenSci136 Wins NMPA Clinical Trial Approval for Sjögren’s Syndrome – Proprietary Dual-Target BAFF/APRIL Antagonist Advances Changchun High-Tech’s Autoimmune Pipeline

Xiangxue Pharma's XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China

Xiangxue Pharma’s XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Centergate TechnologiesClinical trial approval / initiation

Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment

Clinical trial resultsNovartis

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

ADC / XDCBreakthrough therapy

SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC

ADC / XDCHeidelberg Pharma

Huadong Medicine and Heidelberg Pharma Expand ADC Collaboration to Advance Next-Generation Bispecific Conjugates

Show More